-
1.
公开(公告)号:US12061613B2
公开(公告)日:2024-08-13
申请号:US17383024
申请日:2021-07-22
申请人: Accencio LLC
发明人: Kevin Brown , Kevin Brogle
IPC分类号: G06F16/9535 , G01N35/00 , G06F16/22 , G06F16/2457 , G06F16/248 , G06F16/25 , G06F16/951 , G06N20/00
CPC分类号: G06F16/24578 , G01N35/00722 , G06F16/2264 , G06F16/248 , G06F16/254 , G06N20/00 , G01N2035/0091
摘要: The present invention is directed to generating an n-dimensional map using the results of a query for compounds enumerated within a collection of documents describing a particular biological target of interest and a curated set of compounds not enumerated in the collection of documents. Both sets of compounds (document coded and curated coded) are converted into coded forms and placed in the n-dimensional map. One or more processors are configured to evaluate the distance between the curated coded forms and the closest cluster of document coded forms. Based on the distance between a coded form and the document coded forms, the curated coded forms can be ranked regarding the likelihood of interacting with the particular biological target.
-
公开(公告)号:US12083099B2
公开(公告)日:2024-09-10
申请号:US17513284
申请日:2021-10-28
申请人: Accencio LLC
发明人: Kevin Brown , Kevin Brogle
IPC分类号: A61K31/4709 , A61K9/00 , A61K31/407
CPC分类号: A61K31/407 , A61K9/0014 , A61K31/4709
摘要: The present disclosure relates to a method of reducing or arresting viral load in a subject infected with a coronavirus, the method comprising the step of administering to the subject a therapeutically effective amount of a viral protease inhibitor. In some embodiments, the subject is a human. In one embodiment, the coronavirus is SARS-COV-19 and the viral protease inhibitor is E)-N-(4-(3-(tert-butyl)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2-methoxystyryl)phenyl)methanesulfonamide; (R)-3-((2S,3S)-2-hydroxy-3-(3-hydroxy-2-methylbenzamido)-4-phenylbutanoyl)-5,5-dimethyl-N-(2-methylbenzyl)thiazolidine-4-carboxamide; R)—N-allyl-3-((2S,3S)-2-hydroxy-3-(3-hydroxy-2-methylbenzamido)-4-phenylbutanoyl)-5,5-dimethylthiazolidine-4-carboxamide; (4-((N-(5-cyclopropyl-2-(4-fluorophenyl)-3-(methylcarbamoyl)benzofuran-6-yl)methylsulfonamido)methyl)-2-fluorophenyl)boronic acid or salts thereof.
-
公开(公告)号:US20220223232A1
公开(公告)日:2022-07-14
申请号:US17571840
申请日:2022-01-10
申请人: Accencio LLC
发明人: Kevin Brown , Kevin Brogle
摘要: The present invention is directed to generating an n-dimensional map using the results of a query for compounds enumerated within a collection of documents describing a particular biological target of interest and a curated set of sequences, such as but not limited to, protein or nucleotide sequences not enumerated in the collection of documents. Both sets of sequences (document coded and curated coded) are converted into coded forms and placed in the n-dimensional map. One or more processors are configured to evaluate the distance between the curated coded forms and the closest cluster of document coded forms. Based on the distance between a coded form and the document coded forms, the curated coded forms can be ranked regarding the likelihood of interacting with the particular biological target.
-
公开(公告)号:US20240016813A1
公开(公告)日:2024-01-18
申请号:US18044964
申请日:2021-09-09
申请人: Accencio LLC
发明人: Kevin Brown , Kevin Brogle
IPC分类号: A61K31/55 , A61K31/454
CPC分类号: A61K31/55 , A61K31/454
摘要: The present disclosure relates to methods of treating at least one symptom of a coronavirus infection, or preventing an acute inflammatory response, e.g., a cytokine storm in a coronavirus patient, in particular a SARS-CoV-19 patient, by administering an angiontensin converting enzyme-2 (ACE2) modulator.
-
5.
公开(公告)号:US20230310469A1
公开(公告)日:2023-10-05
申请号:US18023600
申请日:2021-08-30
申请人: Accencio LLC
发明人: Kevin Brown , Kevin Brogle
IPC分类号: A61K31/683 , A61K31/708 , A61K31/55 , A61K31/4375 , A61K31/522 , A61K9/00
CPC分类号: A61K31/683 , A61K31/708 , A61K31/55 , A61K31/4375 , A61K31/522 , A61K9/0014
摘要: The present disclosure relates to methods of treating at least one symptom of a coronavirus infection, or preventing an acute inflammatory response, e.g., a cytokine storm in a coronavirus patient, in particular a SARS-CoV-19 patient, by administering a Toll-Like-Receptor (TLR) agonist, in particular a TLR-7 or TLR-8 agonist.
-
公开(公告)号:US20230113114A1
公开(公告)日:2023-04-13
申请号:US17513284
申请日:2021-10-28
申请人: Accencio LLC
发明人: Kevin Brown , Kevin Brogle
IPC分类号: A61K31/407 , A61K9/00 , A61K31/4709
摘要: The present disclosure relates to a method of reducing or arresting viral load in a subject infected with a coronavirus, the method comprising the step of administering to the subject a therapeutically effective amount of a viral protease inhibitor. In some embodiments, the subject is a human. In one embodiment, the coronavirus is SARS-CoV-19 and the viral protease inhibitor is E)-N-(4-(3-(tert-butyl)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2-methoxystyryl)phenyl)methanesulfonamide; (R)-3-((2S,3S)-2-hydroxy-3-(3-hydroxy-2-methylbenzamido)-4-phenylbutanoyl)-5,5-dimethyl-N-(2-methylbenzyl)thiazolidine-4-carboxamide; R)—N-allyl-3-((2S,3S)-2-hydroxy-3-(3-hydroxy-2-methylbenzamido)-4-phenylbutanoyl)-5,5-dimethylthiazolidine-4-carboxamide; (4-((N-(5-cyclopropyl-2-(4-fluorophenyl)-3-(methylcarbamoyl)benzofuran-6-yl)methylsulfonamido)methyl)-2-fluorophenyl)boronic acid or salts thereof.
-
7.
公开(公告)号:US20220027374A1
公开(公告)日:2022-01-27
申请号:US17383024
申请日:2021-07-22
申请人: Accencio LLC
发明人: Kevin Brown , Kevin Brogle
IPC分类号: G06F16/2457 , G06F16/25 , G06F16/22 , G06F16/248 , G06N20/00 , G01N35/00
摘要: The present invention is directed to generating an n-dimensional map using the results of a query for compounds enumerated within a collection of documents describing a particular biological target of interest and a curated set of compounds not enumerated in the collection of documents. Both sets of compounds (document coded and curated coded) are converted into coded forms and placed in the n-dimensional map. One or more processors are configured to evaluate the distance between the curated coded forms and the closest cluster of document coded forms. Based on the distance between a coded form and the document coded forms, the curated coded forms can be ranked regarding the likelihood of interacting with the particular biological target.
-
-
-
-
-
-